These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 1683626)

  • 61. [Autistic hebephrenia: concepts and findings].
    Althaus G; Kamolz S; Franzek E; Pfuhlmann B
    Fortschr Neurol Psychiatr; 2001 Oct; 69(10):482-7. PubMed ID: 11602925
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Effect of anticholinergic medication on positive and negative symptoms in medication-free schizophrenic patients.
    Tandon R; Mann NA; Eisner WH; Coppard N
    Psychiatry Res; 1990 Mar; 31(3):235-41. PubMed ID: 2333355
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Neuroleptic-withdrawal cachexia.
    Mikkelsen EJ; Albert LG; Upadhyaya A
    N Engl J Med; 1988 Apr; 318(14):929. PubMed ID: 2895425
    [No Abstract]   [Full Text] [Related]  

  • 64. Neuroleptics and depression.
    Wistedt B
    Arch Gen Psychiatry; 1982 Jun; 39(6):745. PubMed ID: 6124226
    [No Abstract]   [Full Text] [Related]  

  • 65. A case of auto-erotic asphyxia in a long-term psychiatric setting.
    Quinn J; Twomey P
    Psychopathology; 1998; 31(4):169-73. PubMed ID: 9697159
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The need for long-term neuroleptic treatment in schizophrenia.
    Dencker SJ
    Acta Psychiatr Scand Suppl; 1981; 291():29-43. PubMed ID: 6113733
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Psychotic symptoms following oxycodone withdrawal, case report and update.
    Casado-Espada NM; Martín C; De La Iglesia-Larrad JI; De Alarcón R; Fombellida CI; Fernández-Martín LC; Roncero C
    Eur Rev Med Pharmacol Sci; 2019 Jul; 23(14):6315-6320. PubMed ID: 31364138
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Life-threatening neuroleptic withdrawal emergent syndrome resembling status dystonicus.
    Pugin D; Bally J; Horvath J; Pollak P; Gasche Y; Burkhard PR
    Parkinsonism Relat Disord; 2017 Feb; 35():96-97. PubMed ID: 27914829
    [No Abstract]   [Full Text] [Related]  

  • 69. Attentional and clinical neuroleptic response in schizophrenia: a study with the continuous performance test.
    Serper MR; Harvey PD; Davidson M
    Cogn Neuropsychiatry; 1997 Nov; 2(4):241-9. PubMed ID: 25419792
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The mechanism of neuroleptic withdrawal.
    Eppel AB; Mishra R
    Can J Psychiatry; 1984 Oct; 29(6):508-9. PubMed ID: 6149010
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Neuroleptic-induced psychotic deterioration in a schizophrenic.
    Gershon S
    J Clin Psychopharmacol; 1981 Mar; 1(2):96. PubMed ID: 6117581
    [No Abstract]   [Full Text] [Related]  

  • 72. Object-name selection in psychiatric patients before and after neuroleptic therapy.
    Calvert JE; Babiker IE; Harris JP; Phillipson OT; Ford MF; Antebi DL
    J Psychopharmacol; 1990 Jan; 4(2):75-82. PubMed ID: 22282931
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Saliva secretion disorder in a schizophrenic patient - a problem in dental and psychiatric treatment: a case report.
    Moś DM
    Ann Gen Psychiatry; 2015; 14():14. PubMed ID: 25810747
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Zuclopenthixol, D(1)/D(2) antagonist, for treatment of chronic aggressive schizophrenia and psychotic oligophrenic patients.
    Grinshpoon A; Moskowitz M; Valevski A; Kreizman A; Palei L; Mar M; Weizman A
    Eur Psychiatry; 1998 Aug; 13(5):273-5. PubMed ID: 19698639
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The schizophrenic sequence: withdrawal, disorganization, psychotic reorganization.
    JENKINS RL
    Am J Orthopsychiatry; 1952 Oct; 22(4):738-48. PubMed ID: 12996653
    [No Abstract]   [Full Text] [Related]  

  • 76. Reactions to novel and familiar stimuli as a function of schizophrenic withdrawal.
    MCREYNOLDS P
    Percept Mot Skills; 1963 Jun; 16():847-50. PubMed ID: 13932278
    [No Abstract]   [Full Text] [Related]  

  • 77. Abstract withdrawal.
    Gut; 2008 Mar; 57(3):427-8. PubMed ID: 18320608
    [No Abstract]   [Full Text] [Related]  

  • 78. [Therapeutic and non-pathological symptoms proper].
    RESTREPO JM
    An Academ Med Medellin; 1946-1947; 3(5):357-71. PubMed ID: 20272384
    [No Abstract]   [Full Text] [Related]  

  • 79. Negative withdrawal time: simple and efficient.
    Kidambi TD; Terdiman JP; Lee JK
    Gastrointest Endosc; 2018 Oct; 88(4):781. PubMed ID: 30217248
    [No Abstract]   [Full Text] [Related]  

  • 80. Antipsychotic reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia.
    Bergman H; Rathbone J; Agarwal V; Soares-Weiser K
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD000459. PubMed ID: 29409162
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.